global-hematology-2019-keynote

4 / 4

Global Hematology 2019 Hematology and Blood Disorders | Volume 2
Page 15
July 25-26, 2019 | Amsterdam, Netherlands
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
4th International Conference on
HEMATOLOGY AND
BONE MARROW TRANSPLANTATION
1000x109/l and normocellular megakaryocytic (M) proliferation of immature megakaryocytes with cloud-like hyperchromatic
nuclei or prefibrotic dual megakaryocytic granulocytic (MG) myeloproliferation followed by various degrees of bone marrow
fibrosis. Natural history and life expectancy of MPN patients are related to the response to treatment and the degree of anae-
mia, splenomegaly, myelofibrosis and constitutional symptoms. The acquisition of epigenetic mutations at increasing age on
top of MPN disease burden independently predicts unfavourable outcome in JAK2V617F, MPL515 and CALR mutated MPNs,
which mutually exclude each other. Current treatment options in MPN include low dose aspirin in JAK2 and MPL mutated ET,
phlebotomy on top of aspirin in PV, pegylated interferon in intermediate stages of PV and CALR andMPL mutated ET followed
by hydroxyurea and or ruxolitinib in the hypercellular stages of PV and MF.